1738P Association of ZNF479 mutation with tumor mutation burden and survival in lung cancer patients treated with immune checkpoint inhibitors

Abstract

Lung cancer has always been a high incidence of malignant tumor. Immune checkpoint inhibitors (ICIs) including atezolizumab, pembrolizumab have shown durable responses and have been approved by FDA. However, ICIs demonstrate antitumor effects only in a fraction of patients, and research exploring the association between gene mutation and clinical benefit is limited. ZNF479 (encoding zinc finger protein 479) mutation rate is high in lung cancer. Studies have shown that lymphoid and myeloid expressed different sets of the expression of ZNF479 and other closely related genes, which means that ZNF479 may be related to immunity.